<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03661138</url>
  </required_header>
  <id_info>
    <org_study_id>M17-377</org_study_id>
    <nct_id>NCT03661138</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 3 Randomized, Multicenter, Double-Blind Study to Evaluate the Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects in Japan With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety of upadacitinib combined with topical
      corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe
      atopic dermatitis (AD) who are candidates for systemic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing adverse events</measure>
    <time_frame>Up to 141 Weeks</time_frame>
    <description>Adverse events are defined as those that began or worsened in severity after the first dose of study drug but within 30 days after the last dose of study drug.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">272</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Upadacitinib is administered orally.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for upadacitinib</intervention_name>
    <description>Placebo is administered orally.</description>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Corticosteroids (TCS)</intervention_name>
    <description>It is administered concomitantly with upadacitinib or placebo.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index
             (EASI), Investigator's Global Assessment (IGA), Body surface area (BSA), and pruritus.

          -  Candidate for systemic therapy or have recently required systemic therapy for atopic
             dermatitis.

          -  Able to tolerate topical corticosteroids for atopic dermatitis lesions.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor.

          -  Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to
             the study.

          -  Requirement of prohibited medications during the study.

          -  Female participant who is pregnant, breastfeeding, or considering pregnancy during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Clinic /ID# 206558</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4640821</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital /ID# 207566</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yasumoto Dermatology Clinic /ID# 206480</name>
      <address>
        <city>Chikushino-shi</city>
        <state>Fukuoka</state>
        <zip>8180083</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiryu Dermatology Clinic /ID# 206044</name>
      <address>
        <city>Fukuoka City</city>
        <state>Fukuoka</state>
        <zip>8130044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuda Tomoko Dermatological Clinic /ID# 206288</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>8190167</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Matsuo Clinic /ID# 207323</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>8190373</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higuchi Dermatology Urology Clinic /ID# 206287</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <zip>8160802</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiryu Kosei General Hospital /ID# 206155</name>
      <address>
        <city>Kiryu-shi</city>
        <state>Gunma</state>
        <zip>376-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital /ID# 207016</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuyama City Hospital /ID# 206761</name>
      <address>
        <city>Fukuyama-shi</city>
        <state>Hiroshima</state>
        <zip>721-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital /ID# 206521</name>
      <address>
        <city>Asahikawa-shi</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitago Dermatology Clinic /ID# 207025</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kato Dermatology Clinic /ID# 206561</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0030026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206519</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki General Medical Center /ID# 206974</name>
      <address>
        <city>Amagasaki-shi</city>
        <state>Hyogo</state>
        <zip>660-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital /ID# 206200</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation Kojunkai Kosugi Dermatology Clinic /ID# 206766</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Musashi Kosugi Hospital /ID# 206656</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suizenji Dermatology Clinic /ID# 205871</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>8620950</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital /ID# 206118</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagaoka Red Cross Hospital /ID# 209817</name>
      <address>
        <city>Nagaoka-shi</city>
        <state>Niigata</state>
        <zip>940-2108</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isonokami dermatological clinic /ID# 206923</name>
      <address>
        <city>Daito-shi</city>
        <state>Osaka</state>
        <zip>5740046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation Kojinkai Yoshioka Dermatology Clinic /ID# 209704</name>
      <address>
        <city>Neyagawa-shi</city>
        <state>Osaka</state>
        <zip>572-0838</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka General Hospital /ID# 207122</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <zip>420-8527</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Seikakai Mildix Skin Clinic /ID# 206829</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <zip>1200034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuwa clinic /ID# 206760</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1030027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosono Clinic /ID# 205953</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital /ID# 205942</name>
      <address>
        <city>Ichinomiya-shi</city>
        <state>Tokyo</state>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mita Dermatology Clinic /ID# 206694</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>1080014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Jitai-kai Nakano Dermatology Clinic /ID# 206882</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <zip>1640001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsuyama Dermatology Clinic /ID# 205998</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <zip>1650026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Rosai Hospital /ID# 205809</name>
      <address>
        <city>Ohta-ku</city>
        <state>Tokyo</state>
        <zip>143-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miu Skin Clinic /ID# 206911</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>114-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampopo Dermatology Clinic /ID# 207013</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>1430023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naoko Dermatology Clinic /ID# 205334</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <zip>1580097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tachikawa Dermatology Clinic /ID# 206996</name>
      <address>
        <city>Tachikawa-shi</city>
        <state>Tokyo</state>
        <zip>1900023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital /ID# 205918</name>
      <address>
        <city>Amagasaki</city>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaesu Nihonbashi Skin Clinic /ID# 207125</name>
      <address>
        <city>Chuo-ku</city>
        <zip>1030028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital /ID# 206657</name>
      <address>
        <city>Isehara</city>
        <zip>259-1143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kizawa Memorial Hospital /ID# 205684</name>
      <address>
        <city>Minokamo</city>
        <zip>505-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hosp /ID# 206186</name>
      <address>
        <city>Tokyo</city>
        <zip>173-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toyama Prefectural Ctr Hosp /ID# 206286</name>
      <address>
        <city>Toyama</city>
        <zip>930-0975</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Rosai Hospital /ID# 206648</name>
      <address>
        <city>Yokohama</city>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upadacitinib</keyword>
  <keyword>Topical Corticosteroids</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

